Press Release<< Back
Repros Announces New CEO
"As Repros continues to advance its pipeline, the board will be conducting a search for a CEO with the appropriate experience to lead the Company's next stage of growth," said
Prior to becoming CEO of CavtheRx,
About Repros Therapeutics Inc.®
Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.
Any statements made by the Company that are not historical facts contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to various risks, uncertainties and other factors that could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as "may,"
"will," "expect," "anticipate," "continue," "estimate," "project," "intend," "believe," "plan," "seek," "could," "can," "should" or similar expressions. These statements are based on assumptions that the Company has made in light of the Company's experience in the industry, as well as the Company's perceptions of historical trends, current conditions, expected future developments and other factors the Company believes are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to the Company's pipeline and CEO search. Risks associated with achieving forward-looking statements are identified in the Company's most recent Annual Report on Form 10-K and in any subsequent quarterly reports on Form 10-Q. These documents are available on request from
CONTACT: Investor Relations:
Thomas Hoffmann The Trout Group(646) 378-2931 email@example.com
News Provided by Acquire Media